FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
Sponsor: Actuate Therapeutics Inc.
This PHASE2 trial investigates Pancreatic Adenocarcinoma and Pancreatic Adenocarcinoma Metastatic and is currently ongoing. Actuate Therapeutics Inc. leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jul 2022 — Apr 2024 [monthly]
Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — May 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Actuate Therapeutics Inc.
- Colin D. Weekes, M.D., PhD
- Lustgarten Foundation
For direct contact, visit the study record on ClinicalTrials.gov .